STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients

Core Insights - STRATA Skin Sciences is working with CMS to obtain temporary codes for expanded reimbursement of its XTRAC excimer laser treatment, aiming for implementation as early as the 2026 rule cycle [2][3] - The American Medical Association has approved updates to CPT codes, expanding reimbursement eligibility for XTRAC treatments to include various inflammatory and autoimmune skin conditions effective January 1, 2027 [2] - STRATA's efforts could potentially triple the addressable patient population, benefiting over 30 million individuals with chronic skin conditions [3] Company Developments - STRATA has received significant support from legislators, patient advocacy groups, and academic leaders, reinforcing confidence in the efficacy of Excimer Laser therapy [4] - Recent peer-reviewed studies have confirmed the safety and effectiveness of combining 308-nm excimer laser therapy with JAK inhibitors for treating vitiligo, with one study showing a 100% overall response rate [5][6] - The company is involved in ongoing litigation against LaserOptek America, with the Federal District Court agreeing to add LaserOptek Korea as a defendant, indicating potential for significant damages [7][8] Product and Market Strategy - STRATA's XTRAC excimer laser is positioned as a leading drug-free option for treating skin conditions, with a focus on enhancing patient outcomes [4][9] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support to promote its technologies [11] - STRATA's intellectual property portfolio includes patents for localized treatment methods, positioning the company for future growth in the dermatology market [9]